Future Medicine Co., Ltd.
Future Medicine develops FM101, FM301, FM2L and FM801 for MASH, glaucoma, cancer and obesity via its FOCUS platform.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2015 and listed on KONEX in 2022, Future Medicine is a synthetic drug developer. Using its nucleoside-derivative FOCUS platform, it develops FM101 for MASH, glaucoma, diabetic nephropathy and PBC, plus FM301, FM2L and FM801. FM101 completed European Phase 1 for MASH and entered Phase 2a, gained Australian IND approval for glaucoma, and received US FDA rare disease status for PBC.
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2023 (Phase 2a 1)
- Phase 2aFM1012023-02-01
10 trial sites
R&D and key agreements
Source: DART corporate disclosureFM101 · 대사이상지방간염(MASH) · 유럽 임상1상 종료, 유럽/한국 다국가 임상2a상 진행 중 · Anti-inflammatory/anti-fibrotic candidate
FM101 · 녹내장(Glaucoma) · 유럽 임상1상 종료, 호주 임상2a상 IND 승인 · Anti-inflammatory/anti-fibrotic candidate
FM101 · 당뇨병성 신증 · 유럽 임상1상 종료 · Anti-inflammatory/anti-fibrotic candidate
FM101 · 원발성 담즙성 담관염(PBC) · 유럽 임상1상 종료 · Designated as a rare disease treatment by the US FDA
FM301 · 폐암, 대장암 등 · 비임상 진행 중 · Multi-target anticancer agent
FM2L · COVID-19 · 비임상 진행 중 · Antiviral agent
FM801 · 비만 · 비임상 진행 중 · Obesity treatment candidate
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition